Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).

ABSTRACT:

Background

Cardiovascular disease (CVD) is more frequent among people with HIV (PWH) and may relate to traditional and nontraditional factors, including inflammation and immune activation. A critical need exists to develop effective strategies to prevent CVD in this population.

Methods

The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) (A5332) is a prospective, randomized, placebo-controlled trial of a statin strategy for the primary prevention of major adverse cardiovascular events (MACE) in PWH with low to moderate traditional risk. At least 7,500 PWH, 40-75 years of age, on stable antiretroviral therapy, will be randomized to pitavastatin calcium (4 mg/d) or identical placebo and followed for up to 8 years. Participants are enrolled based on the 2013 Americ

SUBMITTER: Grinspoon SK 

PROVIDER: S-EPMC6535121 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature